What is dMed Biopharmaceutical?
Founded in 2016, dMed Biopharmaceutical operates as a full-service Clinical Contract Research Organization (CRO). With a robust team of nearly 700 professionals across China and the U.S., dMed aims to be a next-generation clinical development partner. The organization empowers its clients to bring innovative solutions to patients globally, with a strategic focus on the U.S. and China, the two largest healthcare markets. Its U.S. operations include Target Health, a CRO with specialized expertise in digital capabilities and regulatory affairs, enhancing its comprehensive service offering.
How much funding has dMed Biopharmaceutical raised?
dMed Biopharmaceutical has raised a total of $158M across 3 funding rounds:
Series A
$8M
Series B
$50M
Series C
$100M
Series A (2016): $8M with participation from Zai Lab, Qiming Venture Capital, and Tairui Investment
Series B (2019): $50M led by Legend Capital, Qiming Venture Partners, Vivo Capital, and Lilly Asia Ventures
Series C (2020): $100M supported by E Fund Management Co. Ltd, Kaiser Foundation Hospital, Fidelity Management Services Inc, and Sequoia Capital Operations LLC
Key Investors in dMed Biopharmaceutical
Qiming Venture Capital
Qiming Venture Capital is a prominent venture capital firm that focuses on investing in innovative companies across various sectors, including technology, healthcare, and artificial intelligence. They aim to support entrepreneurs by providing industry resources, strategic guidance, and fostering strong relationships with stakeholders.
Sequoia Capital Operations LLC
Sequoia Capital is a global venture capital firm known for its early investments in major technology companies. They actively partner with entrepreneurs to build market-leading businesses, providing strategic guidance and capital across various stages of growth.
Legend Capital
Legend Capital is a private equity fund manager focused on innovation and growth enterprises, particularly those with operations in or related to China. They manage significant capital across USD and RMB funds, investing in a broad range of companies.
What's next for dMed Biopharmaceutical?
The substantial enterprise-level capital infusion positions dMed Biopharmaceutical for accelerated growth and enhanced service capabilities. This strategic financing is anticipated to bolster its research and development initiatives, expand its operational footprint, and potentially facilitate strategic partnerships or acquisitions. The company's focus on bridging the U.S. and China markets, coupled with its CRO expertise, suggests a strategic push towards becoming a leading global player in clinical development and pharmaceutical innovation.
See full dMed Biopharmaceutical company page
